BioHarvest Sciences' Proprietary Olive Cell Composition Attains Commercial Readiness, Now Available For Licensing And Commercialization

BioHarvest Sciences has announced that its proprietary Olive Cell Composition has achieved commercial readiness, completing development and commercial-scale manufacturing at its GMP facility. The asset, developed through Botanical Synthesis™, has passed the self-affirmed GRAS process and is now available for licensing and commercialization. The olive-derived Verbascoside composition shows promising preclinical activity in liver steatosis and fibrosis models, indicating potential applications across various health and wellness categories.